| Document Date: 2009-10-02 13:00:02
Open Document File Size: 66,55 KBShare Result on Facebook
City City / Somerset / / Company Baker Norton Pharmaceuticals Inc. / MedPointe Pharmaceuticals MedPointe Healthcare Inc. / Questcor Pharmaceuticals Inc. Union / Ames / / Country New Zealand / United States / / Event Product Recall / Product Issues / FDA Phase / / Facility Store DORAL / These laboratory / Laboratory Tests / / IndustryTerm related drug products / treatment of insomnia / machinery / food / dangerous machinery / receptor site / / MedicalCondition medical illness / Drug addiction / dysarthria / headache / CNS depression / urinary retention / seizures / relative deficiency / urinary incontinence / hallucinations / coma / nausea / anaphylaxis / angioedema involving / tremor / drowsiness / physical disorder / disorder / diarrhea / hypersensitivity / chronic pulmonary insufficiency / muscle cramps / Hypokinesia / chronic insomnia / constipation / pruritus / muscle spasticity / alcoholism / Hypotension / ataxia / acute and chronic insomnia / incoordination / abdominal pain / insomnia / convulsions / several other disorders / airway obstruction / disease / dyspnea / amnesia / Carcinogenesis / chronic / psychiatric disorder / vomiting / concomitant disease / angioedema / respiratory depression / dystonia / neonatal CNS depression / hyperkinesia / Withdrawal symptoms / depression / impotence / rash / cataract / syndrome / suspected sleep apnea / / MedicalTreatment hemodialysis / drug therapy / Dialysis / / NaturalFeature Al Lake / / Organization FDA / / Position physician / PRECAUTIONS General / representative / / Product efavirenz / symptoms / DORAL / A patient Medication / diazepam / norepinephrine bitartrate / metaraminol bitartrate / drug / S-018 / / ProvinceOrState New Jersey / California / / PublishedMedium the Medication Guide / / Technology pharmacokinetics / Dialysis / /
SocialTag |
[removed]S-018 FDA final approved labeling text IN[removed]Rev[removed]